Asset
PERAMIVIR
BioCryst Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00705406 | phase2 | completed | 2008-07-01 | 2009-04-01 | BioCryst Pharmaceuticals | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza |
| NCT00958776 | phase3 | terminated | 2009-11-01 | 2012-11-01 | BioCryst Pharmaceuticals | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza |
| NCT01224795 | phase3 | withdrawn | 2010-10-01 | 2010-11-01 | BioCryst Pharmaceuticals | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. |
| NCT00453999 | phase2 | completed | 2007-07-01 | 2008-09-01 | BioCryst Pharmaceuticals | Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza |
| NCT00419263 | phase2 | completed | 2007-01-01 | 2007-09-01 | BioCryst Pharmaceuticals | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 206426 | NDA | BIOCRYST PHARMACEUTICALS INC |
Marketed products (1)
- RAPIVAB